Diffuse Large B-Cell Lymphoma, NOS · Biktarvy — bictegravir/emtricitabine/tenofovir-AF single-tablet ART

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-HIV-BIKTARVY`

ID	`IND-CHRONIC-HIV-PREVENTION-ART`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-DLBCL-NOS`
Sources	`SRC-NCCN-BCELL-2025` `SRC-NIH-AIDS-2024`

Notes

STUB — v0.2-A continuation. ART Regimen authoring is v0.2-A backlog.

Used By

Contraindications

CI-BIKTARVY-RIFAMYCIN - CI-BIKTARVY-RIFAMYCIN
CI-TENOFOVIR-SEVERE-RENAL - CI-TENOFOVIR-SEVERE-RENAL

Indication

IND-CHRONIC-HIV-PREVENTION-OBSERVATION - IND-CHRONIC-HIV-PREVENTION-OBSERVATION
IND-KAPOSI-1L-AIDS-ART - IND-KAPOSI-1L-AIDS-ART

Red flag

RF-CHRONIC-HIV-MALIGNANCY-PREVENTION - HIV infection (positive serology) in an individual without a current AIDS-defining or HIV...

Regimen

REG-HIV-BIKTARVY - Biktarvy — bictegravir/emtricitabine/tenofovir-AF single-tablet ART